Integrated Investment Consultants LLC Buys Shares of 863 United Therapeutics Corporation $UTHR

Key Points

• Integrated Investment Consultants LLC has purchased 863 shares of United Therapeutics Corporation valued at approximately $266,000 during the first quarter.
• United Therapeutics reported $6.41 EPS for the last quarter, missing expectations, and its revenue was 11.7% higher compared to the same quarter last year.
• Several analysts have recently updated their ratings, with Wells Fargo decreasing its target price from $314 to $295 while UBS Group raised theirs from $385 to $415.

Integrated Investment Consultants LLC purchased a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 863 shares of the biotechnology company's stock, valued at approximately $266,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in United Therapeutics by 0.3% during the 1st quarter. Vanguard Group Inc. now owns 4,457,135 shares of the biotechnology company's stock worth $1,374,001,000 after acquiring an additional 15,312 shares during the period. AQR Capital Management LLC lifted its position in United Therapeutics by 0.8% during the 4th quarter. AQR Capital Management LLC now owns 975,444 shares of the biotechnology company's stock worth $344,176,000 after acquiring an additional 7,710 shares during the period. Dimensional Fund Advisors LP lifted its position in United Therapeutics by 0.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 624,711 shares of the biotechnology company's stock worth $192,571,000 after acquiring an additional 4,145 shares during the period. Assetmark Inc. lifted its position in United Therapeutics by 20.8% during the 1st quarter. Assetmark Inc. now owns 518,450 shares of the biotechnology company's stock worth $159,823,000 after acquiring an additional 89,290 shares during the period. Finally, Northern Trust Corp lifted its position in United Therapeutics by 29.1% during the 4th quarter. Northern Trust Corp now owns 488,854 shares of the biotechnology company's stock worth $172,487,000 after acquiring an additional 110,298 shares during the period. Institutional investors and hedge funds own 94.08% of the company's stock.

United Therapeutics Stock Performance

United Therapeutics stock traded up $1.57 during midday trading on Friday, hitting $312.23. 576,473 shares of the company were exchanged, compared to its average volume of 751,685. The firm has a market capitalization of $14.08 billion, a PE ratio of 12.19, a price-to-earnings-growth ratio of 4.73 and a beta of 0.57. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $417.82. The business has a fifty day simple moving average of $297.01 and a two-hundred day simple moving average of $307.34.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing the consensus estimate of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The business had revenue of $798.60 million during the quarter, compared to analysts' expectations of $802.13 million. During the same quarter in the prior year, the firm earned $5.85 EPS. United Therapeutics's revenue for the quarter was up 11.7% on a year-over-year basis. As a group, equities analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Nilda Mesa sold 645 shares of United Therapeutics stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $289.99, for a total value of $187,043.55. Following the completion of the transaction, the director owned 4,883 shares in the company, valued at $1,416,021.17. The trade was a 11.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction dated Thursday, June 12th. The shares were sold at an average price of $279.96, for a total value of $3,079,560.00. Following the completion of the transaction, the executive vice president owned 36,781 shares of the company's stock, valued at approximately $10,297,208.76. This represents a 23.02% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 92,681 shares of company stock worth $28,014,609 in the last 90 days. 10.30% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

UTHR has been the subject of a number of research reports. UBS Group lifted their price target on United Therapeutics from $385.00 to $415.00 and gave the stock a "buy" rating in a research report on Wednesday, August 13th. JPMorgan Chase & Co. lowered their target price on United Therapeutics from $350.00 to $330.00 and set an "overweight" rating on the stock in a research note on Tuesday, July 8th. HC Wainwright set a $400.00 target price on United Therapeutics and gave the stock a "buy" rating in a report on Thursday, July 31st. Wall Street Zen lowered United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, May 2nd. Finally, Wells Fargo & Company dropped their target price on United Therapeutics from $314.00 to $295.00 and set an "equal weight" rating on the stock in a report on Thursday, July 31st. Nine analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $382.00.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.